UBI Pharma
Taiwan Updated 9 July 2026
UBI Pharma is a finished-dose manufacturer based in Taiwan. It appears in 2 regulatory filings across 2 regulators, without an active US DMF or CEP on file. Its filings concentrate with US FDA and JFDA (JO). Its GMP standing is certified by US FDA and MHRA (UK). Its most recent recorded inspection, by US FDA, closed on 6 June 2023 as VAI.
2
registered plants
1 with an FDA FEI number
2
filings
across 2 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 6 June 2023 VAI US FDA
- 20 June 2019 VAI US FDA
- 18 July 2014 VAI US FDA
- 6 August 2012 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| HSINCHU COUNTY, Taiwan | Not on file |
| Taiwan, Taiwan | 3004713402 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | 1 | 1 |
| JFDA (JO) | 1 | None |
| MHRA (UK) | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. UBI Pharma comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 6 June 2023.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates